GUANGZHOU YIDIAN MEDICAL EQUIPMENT CO.,LTD.
China
Manufacturer/ Producer
Super External Counter-Pulsation Device (SECP)The device can be used for the treatment of: (1).Coronary heart disease, angina pectoris and myocardial infarction.(2).Cerebral arteriosclerosis, cerebral thrombosis, cerebral embolism, paralysis agitation, cerebral ischemia of vertebral-basilar artery, sequel of cerebrovascular accident and other encephalopathy caused by ischemia. (3).Embolism of retinal artery, central serous retinopathy, and optic atrophy and nerve disease for shortage of blood. (4).Sudden deafness. (5).Other ischemic diseases and sequels caused by arteriosclerosis and disturbance of circulation, therapy after operation of coronary bypass. (6).Tiredness due to excessive physical exercise. (7).Rehabilitation and health-care purposes.
Website
Manufacturer/ Producer
NO.18, 2nd Hanxi Industrial Zone, Zhongcun, Panyu
511400 Guangzhou - China
Company info
Key figures
-
- Company headcount
- 51 – 100
-
- Sales staff
- 101 – 200
-
- % of export sales
- 50%
Organisation
-
- Year established
- 2005
-
- pages.epage-home.site-status
- Registered office
-
- Main activity
- Manufacturer/ Producer
Business info
Trading areas
- International
Banks
- TT
Delivery areas
Activities of GUANGZHOU YIDIAN MEDICAL EQUIPMENT CO.,LTD.
- Medical and surgical instruments
- eecp
- Enhanced External Counterpulsation
europages also recommends
A selection of companies related to the activity:
A selection of products that might interest you
MPS MICRO PRECISION SYSTEMS AG
Switzerland
Novostia, a Swiss startup founded in 2017, has entrusted MPS with the manufacture of its TRIFLO artificial valve, a revolutionary aortic prosthesis on several levels. Thanks to its aerodynamic design, the presence of three leaflets and the absence of physical pivot axes for the leaflets, the TRIFLO valve aims to satisfy the following three criteria: - A device lifespan at least equal to that of the patient, to avoid the need for a second surgical procedure. This means more than 30 million flap openings and closures per year, with no leaks, blockages, cracks, ruptures or flap escapes. - The artificial valve must not lead to thrombosis, so that patients do not need to take anticoagulants. - Operation (flap opening and closing, blood flow through the valve) must be as silent as possible, so as not to disturb the patient or those around him, day or night. The TRIFLO device is in clinical trial and is not approved for sale.
Request for quotes
Create one request and get multiple quotes form verified suppliers.
- Only relevant suppliers
- Data privacy compliant
- 100% free